Manufacture, Characterization, and Pharmacodynamic Evaluation of Engineered Ipratropium Bromide Particles

Author： Taylor Michael   Hickey Anthony   VanOort Michiel  

Publisher： Informa Healthcare

ISSN： 1083-7450

Source： Pharmaceutical Development and Technology, Vol.11, Iss.3, 2006-09, pp. : 321-336

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

One-Year Evaluation of the Safety and Efficacy of Ipratropium Bromide HFA and CFC Inhalation Aerosols in Patients with Chronic Obstructive Pulmonary Disease

By Brazinsky S.A.  

Clinical Drug Investigation, Vol. 23, Iss. 3, 2003-01 ,pp. : 181-191

Adis International

Access to resources Recommend Favorite

Ipratropium bromide use in Australia outside guidelines

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 348, 2002-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Enhanced fenoterol/ipratropium bromide delivery in COPD

By  

Inpharma, Vol. 1, Iss. 1443, 2004-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Ipratropium bromide: Anisocoria in an infant: case report

By  

Reactions Weekly, Vol. 1, Iss. 1363, 2011-01 ,pp. : 25-26

Adis International

Access to resources Recommend Favorite

Ipratropium bromide/salbutamol interaction: Mydriasis: case report

By  

Reactions Weekly, Vol. 1, Iss. 1288, 2010-01 ,pp. : 24-25

Adis International

Access to resources Recommend Favorite